LT3129487T - Patobulinti nukleorūgščių konstruktai, skirti eukariotinio geno raiškai - Google Patents

Patobulinti nukleorūgščių konstruktai, skirti eukariotinio geno raiškai

Info

Publication number
LT3129487T
LT3129487T LTEP15776901.9T LT15776901T LT3129487T LT 3129487 T LT3129487 T LT 3129487T LT 15776901 T LT15776901 T LT 15776901T LT 3129487 T LT3129487 T LT 3129487T
Authority
LT
Lithuania
Prior art keywords
nucleic acid
gene expression
acid constructs
eukaryotic gene
enhanced nucleic
Prior art date
Application number
LTEP15776901.9T
Other languages
English (en)
Inventor
Jeremy Minshull
Mark Welch
Sridhar Govindrajan
Kate CAVES
Original Assignee
Dna Twopointo Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54264598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3129487(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dna Twopointo Inc. filed Critical Dna Twopointo Inc.
Publication of LT3129487T publication Critical patent/LT3129487T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43586—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from silkworms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/40—Vector systems having a special element relevant for transcription being an insulator
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Insects & Arthropods (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LTEP15776901.9T 2014-04-09 2015-04-09 Patobulinti nukleorūgščių konstruktai, skirti eukariotinio geno raiškai LT3129487T (lt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461977474P 2014-04-09 2014-04-09
US201462003397P 2014-05-27 2014-05-27
US201462046875P 2014-09-05 2014-09-05
US201462046705P 2014-09-05 2014-09-05
US201462069656P 2014-10-28 2014-10-28
US201562120522P 2015-02-25 2015-02-25
PCT/US2015/025209 WO2015157579A2 (en) 2014-04-09 2015-04-09 Enhanced nucleic acid constructs for eukaryotic gene expression

Publications (1)

Publication Number Publication Date
LT3129487T true LT3129487T (lt) 2020-12-28

Family

ID=54264598

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP15776901.9T LT3129487T (lt) 2014-04-09 2015-04-09 Patobulinti nukleorūgščių konstruktai, skirti eukariotinio geno raiškai

Country Status (8)

Country Link
US (5) US9534234B2 (lt)
EP (2) EP3129487B1 (lt)
CA (2) CA2944887C (lt)
DK (1) DK3129487T3 (lt)
ES (1) ES2835673T3 (lt)
HU (1) HUE052552T2 (lt)
LT (1) LT3129487T (lt)
WO (1) WO2015157579A2 (lt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10344285B2 (en) 2014-04-09 2019-07-09 Dna2.0, Inc. DNA vectors, transposons and transposases for eukaryotic genome modification
US9534234B2 (en) 2014-04-09 2017-01-03 Dna2.0, Inc. Enhanced nucleic acid constructs for eukaryotic gene expression
CA3001312A1 (en) * 2015-10-08 2017-04-13 Dna2.0, Inc. Dna vectors, transposons and transposases for eukaryotic genome modification
EP3368672B1 (en) * 2015-10-27 2020-11-25 Celltheon Corporation Chimeric post-transcriptional regulatory element
CA3004665C (en) * 2015-12-14 2021-08-24 GenomeFrontier Therapeutics, Inc. Transposon system, kit comprising the same, and uses thereof
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
JP6937309B2 (ja) 2016-01-27 2021-09-22 ジャスト−エヴォテック バイオロジックス、インコーポレイテッド ハイブリッドプロモーターおよびその使用
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
US20190300875A1 (en) * 2016-07-11 2019-10-03 The Regents Of The University Of California Bic inhibitor of cry-cry and cry-cib oligomerization/clustering
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
WO2018064681A1 (en) * 2016-09-30 2018-04-05 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
US11278570B2 (en) 2016-12-16 2022-03-22 B-Mogen Biotechnologies, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
JP7275043B2 (ja) 2016-12-16 2023-05-17 ビー－モーゲン・バイオテクノロジーズ，インコーポレーテッド 増大したｈＡＴファミリートランスポゾン媒介遺伝子導入ならびに関連する組成物、システムおよび方法
WO2018170473A1 (en) * 2017-03-17 2018-09-20 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression
US11713468B2 (en) 2017-08-02 2023-08-01 Dna Twopointo Inc. DNA vectors and elements for sustained gene expression in eukaryotic cells
US10329543B2 (en) 2017-10-23 2019-06-25 Poseida Therapeutics, Inc. Modified stem cell memory T cells, methods of making and methods of using same
CN109988759A (zh) * 2017-12-29 2019-07-09 上海细胞治疗研究院 一种在t细胞中具有高转录活性的嵌合启动子
US12281319B2 (en) * 2018-05-18 2025-04-22 Sorbonne Universite Molecular tools and methods for transgene integration and their transposition dependent expression
CN112543808A (zh) 2018-06-21 2021-03-23 比莫根生物科技公司 增强的hAT家族转座子介导的基因转移及相关组合物、系统和方法
US20210324407A1 (en) * 2018-08-29 2021-10-21 Seattle Children's Hospital (dba Seattle Children's Research Institute) Self-inactivating transposase plasmids and uses thereof
BR112021011063A2 (pt) * 2018-12-10 2021-08-31 Amgen Inc. Transposase piggybac mutada
EP4582440A3 (en) * 2018-12-21 2025-10-08 The Regents of the University of California Il-10-containing vaccines and uses thereof
AU2019429609B2 (en) 2019-02-13 2025-09-25 Probiogen Ag Transposase with enhanced insertion site selection properties
BR112021014582A2 (pt) 2019-02-15 2021-10-05 Just-Evotec Biologics, Inc. Sistemas, instalações e processos de biomanufatura automatizados
US11216742B2 (en) 2019-03-04 2022-01-04 Iocurrents, Inc. Data compression and communication using machine learning
CA3125047A1 (en) * 2019-04-08 2020-10-15 Dna Twopointo Inc. Integration of nucleic acid constructs into eukaryotic cells with a transposase from oryzias
MY206450A (en) * 2019-04-08 2024-12-17 Dna Twopointo Inc Transposition of nucleic acid constructs into eukaryotic genomes with a transposase from amyelois
CN114127083B (zh) 2019-05-13 2024-11-15 Dna2.0股份有限公司 使用人工微rna修饰哺乳动物细胞以改变其特性及其产品的组成
WO2020254352A1 (en) * 2019-06-19 2020-12-24 F. Hoffmann-La Roche Ag Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
CN114008081A (zh) * 2019-06-19 2022-02-01 豪夫迈·罗氏有限公司 通过以限定的组织形式靶向整合多个表达盒来产生二价双特异性抗体表达细胞的方法
BR112022003617A2 (pt) * 2019-09-01 2022-09-13 Exuma Biotech Corp Métodos e composições para a modificação e distribuição de linfócitos
BR112022016617A2 (pt) * 2020-02-19 2022-11-22 Wuxi Biologics Ireland Ltd Ácido nucleico, vetor, vetor de transposon, sistema de expressão, ácido nucleico isolado, método para gerar uma célula, célula, método de expressão de uma proteína, proteína, composiçao farmacêutica, sistema de expressão, linhagem celular
WO2021226141A1 (en) 2020-05-04 2021-11-11 Saliogen Therapeutics, Inc. Transposition-based therapies
KR20230038425A (ko) * 2020-07-17 2023-03-20 프로바이오겐 아게 과활성 트랜스포손 및 트랜스포사제
AU2021368557A1 (en) * 2020-10-27 2023-06-08 Adoc Ssf, Llc Compositions and methods for the treatment of cancer using next generation engineered t cell therapy
CN112481289B (zh) * 2020-12-04 2023-06-27 苏州科锐迈德生物医药科技有限公司 一种转录环状rna的重组核酸分子及其在蛋白表达中的应用
US20240087685A1 (en) * 2021-01-20 2024-03-14 The Texas A&M University System Systems and methods for evaluation of structure and property of polynucleotides
EP4284834A1 (en) 2021-01-29 2023-12-06 Merck Sharp & Dohme LLC Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof
EP4308712A4 (en) * 2021-03-15 2025-03-12 Donald Danforth Plant Science Center TARGETED INSERTION VIA TRANSPOSITION
CN113186221A (zh) * 2021-05-24 2021-07-30 广西大学 水牛源lif的制备及其在水牛精原干细胞体外培养的应用
EP4370647A1 (en) 2021-07-15 2024-05-22 Just-Evotec Biologics, Inc. Bidirectional tangential flow filtration (tff) perfusion system
CN113945897B (zh) * 2021-09-03 2024-08-02 西安电子科技大学 一种高超声速平台杂波抑制和运动目标定位方法及装置
AU2022383000A1 (en) * 2021-11-04 2024-05-09 Saliogen Therapeutics, Inc. Mobile elements and chimeric constructs thereof
WO2023154734A2 (en) * 2022-02-08 2023-08-17 Iowa State University Research Foundation, Inc. Mrna expression and delivery systems
CA3266599A1 (en) 2022-09-07 2024-11-07 Quantitative Biosciences, Inc. UNIQUE VARIABLE DOMAIN ANTIBODIES SPECIFIC TO FENTANYL AND USE IN A CONTINUOUS AGGLUTINATION TEST
CN120322561A (zh) 2022-09-30 2025-07-15 勃林格殷格翰国际有限公司 新型转座酶系统
KR20250150697A (ko) * 2023-01-19 2025-10-20 디앤에이 투포인토 인크. 단백질 생물학적 제제 생산용 dna 구조물 구성
WO2025106376A1 (en) * 2023-11-17 2025-05-22 Dna Twopointo Inc. Mammalian cell lines for transient protein production
WO2025128343A1 (en) 2023-12-11 2025-06-19 Just-Evotec Biologics, Inc. Protein expression using trans-splicing and split selectable markers
WO2025250465A1 (en) * 2024-05-28 2025-12-04 Nanjing Probio Biotech Co., Ltd. Vector composition and use thereof
EP4711442A1 (en) 2024-09-15 2026-03-18 Quantitative Biosciences, Inc. Microfluidic chip for the parallel culture of microbial biosensor strains

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681702A (en) 1994-08-30 1997-10-28 Chiron Corporation Reduction of nonspecific hybridization by using novel base-pairing schemes
ZA973367B (en) * 1996-04-19 1997-11-18 Innogenetics Nv Method for typing and detecting HBV.
US6136597A (en) 1997-09-18 2000-10-24 The Salk Institute For Biological Studies RNA export element
US6897066B1 (en) * 1997-09-26 2005-05-24 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
US20030150007A1 (en) 2000-03-21 2003-08-07 Charalambos Savakis Method of generating transgenic organisms using transposons
AU2001270252B2 (en) 2000-07-03 2007-02-08 Catalent Pharma Solutions, Llc Expression vectors
US8005620B2 (en) 2003-08-01 2011-08-23 Dna Twopointo Inc. Systems and methods for biopolymer engineering
TW200613554A (en) * 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
CA2578908C (en) * 2005-03-17 2020-05-26 National Research Council Of Canada Expression vectors for enhanced transient gene expression and mammalian cells expressing them
CN101297031B (zh) * 2005-05-14 2013-06-05 复旦大学 在脊椎动物中作为遗传操作和分析工具的piggyBac
TWI300441B (en) 2005-09-21 2008-09-01 Univ Chung Yuan Christian A polynucleotide with ires activity
WO2007100821A2 (en) 2006-02-28 2007-09-07 University Of Notre Dame Piggybac constructs in vertebrates
WO2008106982A2 (en) * 2007-03-07 2008-09-12 Aarhus Universitet Pig model for atherosclerosis
US20110130444A1 (en) * 2007-05-04 2011-06-02 Stefan Moisyadi Methods and compositions for targeted delivery of gene therapeutic vectors
US20090042297A1 (en) * 2007-06-01 2009-02-12 George Jr Alfred L Piggybac transposon-based vectors and methods of nucleic acid integration
GB0903207D0 (en) * 2009-02-25 2009-04-08 Ucb Pharma Sa Method for expressing multimeric proteins
EP3184632B1 (en) 2009-02-26 2024-04-03 Poseida Therapeutics, Inc. Hyperactive piggybac transposases
US9790489B2 (en) * 2009-10-26 2017-10-17 Chang Gung University Method for performing genetic modification under a drug-free environment and components thereof
EP3483178B1 (en) * 2012-07-31 2020-10-28 AgeX Therapeutics, Inc. Methods to produce hla-g-modified cells
US9534234B2 (en) 2014-04-09 2017-01-03 Dna2.0, Inc. Enhanced nucleic acid constructs for eukaryotic gene expression

Also Published As

Publication number Publication date
US20150291976A1 (en) 2015-10-15
US20150291975A1 (en) 2015-10-15
ES2835673T3 (es) 2021-06-22
US20160333328A1 (en) 2016-11-17
EP3129487A4 (en) 2017-09-13
US20150291977A1 (en) 2015-10-15
EP3670660A1 (en) 2020-06-24
US9534234B2 (en) 2017-01-03
HUE052552T2 (hu) 2021-05-28
CA2944887C (en) 2025-12-09
CA3246595A1 (en) 2025-07-08
DK3129487T3 (da) 2020-11-30
US20160340691A1 (en) 2016-11-24
CA2944887A1 (en) 2015-10-15
US9428767B2 (en) 2016-08-30
US9574209B2 (en) 2017-02-21
EP3129487B1 (en) 2020-10-07
EP3129487A2 (en) 2017-02-15
US9580697B2 (en) 2017-02-28
WO2015157579A3 (en) 2015-12-17
WO2015157579A2 (en) 2015-10-15

Similar Documents

Publication Publication Date Title
LT3129487T (lt) Patobulinti nukleorūgščių konstruktai, skirti eukariotinio geno raiškai
IL252556A0 (en) Nucleic acid constructs for genome editing
DK3134131T3 (en) Nucleic acid vaccines
SI3118311T1 (sl) Protismiselna nukleinska kislina
GB201507119D0 (en) Nucleic Acid Construct
GB201507115D0 (en) Nucleic Acid Construct
GB201507111D0 (en) Nucleic acid construct
GB201507104D0 (en) Nucleic acid construct
GB201507108D0 (en) Nucleic acid construct
PL3094731T3 (pl) Cząsteczki kwasu nukleinowego zmodyfikowane sacharydem
EP3118315A4 (en) Nucleic acid that inhibits expression of irf5
EP3323893A4 (en) BETA2GPI GENE EXPRESSION-INHIBITING NUCLEIC ACID COMPLEX
IL249254B (en) Gene expression system
GB201420428D0 (en) Methods for nucleic acid isolation
EP3095867A4 (en) Nucleic acid capable of inhibiting expression of beta2gpi
GB201409786D0 (en) Nucleic acid amplification system
GB201402630D0 (en) Nucleic acid amplification
HK1235003A1 (zh) 核酸疫苗
GB201410223D0 (en) Nucleic acid amplification system
GB201402370D0 (en) Nucleic acid amplification system